secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0000950170-23-009202
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen reports FY2022 net loss of $36M; cash runway into H2 2024
------------------------------------------------------------------

- Net loss for FY2022 was $36.0M vs $54.6M in FY2021; collaboration revenue $12.5M from Boehringer Ingelheim deal.
- Cash, equivalents and marketable securities $75.8M as of Dec 31, 2022, down from $123.5M a year ago.
- Restructuring reduces operating expenses by ~15% in 2023; cash runway extends into second half of 2024.
- SZN-043 Ph1a enrolled first chronic liver disease patient, data expected end 2023; SZN-1326 Ph1a to reinitiate mid-2023.
- Repurchased 5.38M shares and 1.31M warrants from Consonance for ~$2.7M; Consonance no longer holds shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023009202/0000950170-23-009202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023009202/srzn-20230322.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer